Comparative Pharmacology
Head-to-head clinical analysis: BRYNOVIN versus BUPRENORPHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRYNOVIN versus BUPRENORPHINE.
BRYNOVIN vs BUPRENORPHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Adult: 150 mg orally twice daily.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateBuprenorphine + Torasemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide."
Clinical Note
moderateBuprenorphine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid."
Clinical Note
moderateBuprenorphine + Furosemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide."
Clinical Note
moderateTerminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist
Buprenorphine + Bumetanide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide."